^
Association details:
| Biomarker: | MDM4 mutation |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Regimen: | (Perjeta (pertuzumab) + Herceptin (trastuzumab) + carboplatin + docetaxel + albumin-bound paclitaxel) |
| Direction: | Resistant |
Evidence:
Source:
Title:
An Open-label, Single-center Study Assessing the Efficacy of PH-based Regimen as Neoadjuvant Therapy for HER2-positive Early-stage Breast Cancer: Integrating Genomic Features and Functional Imaging
Published date:
12/02/2023
Excerpt:
HER2-positive EBC patients were prospectively recruited at Fudan University Shanghai Cancer Center between April 2020 and March 2022. All patients received the 1 dose of HP, followed by 6 cycles of docetaxel (T), carboplatin (Cb), and HP....Patients with alterations in PPM1D and RAD21 have a favorable response to the TCbHP regimen. Conversely, alterations in PIK3CA, MDM4, and ZNF217 are associated with treatment resistance.
